Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

LA JOLLA PHARMACEUTICAL CO

Form 4 April 18, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

3235-0287 Number: January 31, Expires:

2005

Section 16. Form 4 or Form 5

SECURITIES

Estimated average burden hours per response... 0.5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person * WISEMAN ANDREW			2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL CO [LJPC]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 6455 NANC	tt) (First) (Middle) MANCY RIDGE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 04/17/2006					Director 10% Owner X Officer (give title Other (specify below) Sen Dir Investor Relations		
				If Amendment, Date Original iled(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SAN DIEGO						Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Table	e I - Non-E	erivative	Securi	ities Acc	quired, Disposed o	of, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ar) Executi any	emed on Date, if /Day/Year)	3. Transacti Code (Instr. 8)	on(A) or (D) (Instr. :	Dispose 3, 4 and (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Stock	03/31/2006			J <u>(1)</u> V	153	A	3.06	16,174	D		
Common								1 209	Ţ	Held by	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

1,209

trust

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4.46	04/17/2006		A	20,301	(2)	04/17/2016	Common Stock	20,301

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

WISEMAN ANDREW 6455 NANCY RIDGE DRIVE SAN DIEGO, CA 92121

Sen Dir Investor Relations

Signatures

/s/ Gail A. Sloan Attorney-in-fact for Andrew Wiseman 04/18/2006

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Acquired pursuant to the Company?s Employee Stock Purchase Plan.
- (2) The stock options vest and become exercisable monthly over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2